Stock Analysis
Revvity, Inc.RVTY
P/E 71.70×· 3Y range 16.74–92.68×· top 8% of history
Sector: Technology · Industry: Laboratory Analytical Instruments
AnalystsBuy25 analystsP/E 71.7× sits at the 92nd percentile of its 3.4195756331279945-year history.
Cash covers 35% of debt · FY 2025.
PMP Verdict
Mixed fundamentals, expensive valuation
Strengths
- Quality77
- Financial Health65
Risks
- Valuation24
- Growth25
Mixed fundamentals at a demanding price.
Bull Case
- ✓Altman Z 3.4 — safe-zone balance sheet
What's happening with RVTY
Profile
Strong earnings quality; valuation, growth and profitability lag behind.
How is each axis scored?
- Valuation24/100 · Weak
- P/E vs own history (92th pct)0/25
- FCF yield (3.3%)12/25
- P/S (5.8x)12/25
- EV/EBIT (52.2x)0/25
- Growth25/100 · Weak
- Revenue CAGR (-7.1%)0/25
- Net income CAGR (-28.9%)0/25
- EPS CAGR 5Y (-29.5%)0/25
- Fwd implied growth (187.0%)25/25
- Profitability35/100 · Weak
- ROIC (3.2%)5/25
- ROE (3.3%)5/25
- Net margin (8.2%)13/25
- Operating margin (12.3%)12/25
- Financial Health65/100 · Moderate
- Altman Z (3.36)25/25
- Current ratio (1.68)18/25
- Interest coverage (4.1x)10/25
- Net cash / debt (D/A 14%)12/25
- Quality77/100 · Strong
- Piotroski F (6/9)15/25
- Beneish M (-2.59)25/25
- FCF conversion (235%)25/25
- Margin stability (σ 9.1%)12/25
- Moat68/100 · Moderate
- ROIC >12% years (0/5 yrs)0/25
- Median gross margin (56.0%)25/25
- FCF-positive years (5/5 yrs)25/25
- Worst-year net margin (worst 8.4%)18/25
Risk Flags
- ⚠Revenue shrinking 7.1%/yr
- ⚠P/E 71.7× at top 8% of 3-year history
About Revvity, Inc.
Revvity is a global life sciences and diagnostics company formed in 2023 following the rebranding of PerkinElmer. Show more
The company operates in two segments: life sciences, which provides reagents and instruments for biopharma and academic research, and signals software, and diagnostics, which offers tools in immunodiagnostics and newborn and reproductive health. Revvity's products and services are sold worldwide, with major markets in the US, Europe, and China.
Headquarters: WALTHAM, MA · Employees: 11,000 · Website ↗
Price History
Weekly Candlestick Chart — up to 5Y
Key Metrics
Financial snapshot · Tap any metric for its definition and grade
TTM Snapshot
trailing twelve months · YoYValuation
24EP/E (TTM)71.7xD
Grade D: ExpensivePrice / TTM EPS (own statements) — vs own 3Y history: 16.7x–92.7x · 92nd pct
P/FCF31.0xC
Grade C: ExpensivePrice / Free Cash Flow per share (Finnhub). Inverse of FCF yield — negative when FCF is negative
FCF Yield3.3%C
Grade C: LowTTM (OCF − CapEx) / Market Cap — vs own 3Y history: -1.6%–5.4% · 41st pct
P/S (TTM)5.85xC
Grade C: ExpensivePrice / TTM Revenue (own statements) — vs own 3Y history: 3.2x–11.9x · 82nd pct
EV/EBIT52.2xD
Grade D: ExpensiveEnterprise value / TTM EBIT (D&A not in our data) — capital-structure neutral — vs own 3Y history: 30.5x–118.6x · 55th pct
EV/Sales6.7xC
Grade C: ExpensiveEnterprise Value / TTM Revenue (Finnhub) — capital-structure neutral sales multiple
Forward P/E25.0xB
Grade B: FairPrice / next-year EPS estimate — shows whether the TTM multiple is rich or just front-loading growth
P/B Ratio2.35xA
Grade A: FairPrice to Book Value. Neg. equity = heavy buybacks
PEG Ratio7.30D
Grade D: ExpensiveFinnhub PEG — their P/E basis ÷ expected EPS growth. Suppressed when their P/E diverges >2× from our TTM P/E (different basis)
Dividend Yield0.18%A
Grade A: PaysTTM dividend yield (Finnhub) — annual dividends / price. None = no dividend; very high yield can signal distress
Payout Ratio13.4%A
Grade A: SafeDividends / Net Income (Finnhub) — share of earnings paid out; >90% or negative = unsustainable
Profitability
35DROIC3.2%D
Grade D: LowNOPAT (EBIT less ~21% tax) / invested capital (equity + debt − cash). Flagship quality metric — durable >15% signals a moat
ROE3.3%D
Grade D: WeakReturn on Equity. Neg. equity = heavy buybacks
ROA2.0%D
Grade D: WeakReturn on Assets (Finnhub) — Net Income / Total Assets; how efficiently assets produce profit
Net Margin8.2%C
Grade C: AverageNet Income / Revenue
Operating Margin12.3%C
Grade C: AverageTTM EBIT / TTM Revenue
Gross Margin55.0%A
Grade A: PremiumGross Profit / Revenue
FCF Margin19.2%A
Grade A: HighFCF / Revenue
True FCF Margin18.3%A
Grade A: HighTTM (OCF − CapEx − SBC) / TTM Revenue — SBC treated as a real cost
Growth
25ERevenue CAGR-7.1%D
Grade D: LowCompound annual revenue growth (up to 5Y depending on data availability)
Net Income CAGR-28.9%D
Grade D: LowCompound annual net income growth (up to 5Y depending on data availability)
EPS CAGR (5Y)-29.5%D
Grade D: LowCompound annual EPS growth over up to 5Y of per-share earnings (own statements). Null when either endpoint EPS ≤ 0
Implied EPS Growth187.0%A
Grade A: HighAnalyst forward EPS (normalized basis) vs our GAAP TTM EPS — different bases, so extreme values usually mark cyclically depressed TTM earnings, not real growth
Dilution (5Y)—
Share count change over 5Y
SBC / Net Income10.3%C
Grade C: MedStock-based comp/Net income. >30% = dilution risk
SBC / Revenue0.8%A
Grade A: LowTTM stock-based comp / TTM Revenue
Financial Health
65BAltman Z-Score3.36A
Grade A: SafeBankruptcy risk. >3 Safe, <1.8 Distress
Current Ratio1.68xC
Grade C: OkCurrent Assets/Liabilities
Quick Ratio1.50xA
Grade A: High(Current Assets − Inventory) / Current Liabilities (Finnhub) — stricter liquidity test, excludes inventory
Interest Coverage4.1xC
Grade C: OkEBIT/Interest. >10 Strong
Debt Repayment3.1yC
Grade C: AverageYears to repay net debt via FCF
Net Debt/EBIT4.8xD
Grade D: HighLeverage. <2x Low, >4x High
Debt/Equity0.36xA
Grade A: LowDebt / Equity: <1 Conservative, >2 Risky. Not meaningful with non-positive equity; shown as unavailable rather than low debt.
Cash / Debt0.35xC
Grade C: PartialCash covers how much of total debt. >1 = could repay all debt from cash
Quality
77B+Piotroski F-Score6/9C
Grade C: AverageFinancial strength 0–9. >7 Strong
Beneish M-Score-2.59A
Grade A: SafeEarnings manipulation risk. < -2.22 Safe
FCF Conversion234.9%A
Grade A: StrongFCF / Net Income
Margin Stability9.1%C
Grade C: AverageEBIT margin std deviation. Lower = stable
Capex / Revenue2.4%A
Grade A: Asset-lightTTM CapEx / TTM Revenue — high % = capital-hungry business
Asset Turnover0.24xD
Grade D: LowRevenue / Total Assets (Finnhub) — how efficiently the asset base generates sales
Insider Transactions
SEC Form 4 · 8 recordsP/S codes are the directional signal; grants, option exercises and tax withholding carry none. Form 4 doesn't flag 10b5-1 plans — scheduled sales may appear within open-market sells.
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Gonzales Anita Filed | Gonzales Anita | SellOpen market sale | -84 | |
Krakowiak Maxwell Filed | Krakowiak Maxwell | SellOpen market sale | -1631 | |
Vohra Tajinder S Filed | Vohra Tajinder S | SellOpen market sale | -7330 | |
MICHAS ALEXIS P Filed | MICHAS ALEXIS P | Gift | -285 | |
Goldberg Joel S Filed | Goldberg Joel S | Gift | +27.8K |
Show 3 more filingsShow fewer filings
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Goldberg Joel S Filed | Goldberg Joel S | Gift | -27785 | |
Singh Prahlad R. Filed | Singh Prahlad R. | Gift | +59.6K | |
Singh Prahlad R. Filed | Singh Prahlad R. | Gift | -59650 |
More metrics — Moat, Per Share, Balance Sheet, MarketHide additional metrics
Moat
68BROIC >12% Years0/5 yrsD
Grade D: WeakShare of completed fiscal years with ROIC > 12% — measures multi-year capital-return durability
Gross Margin (Med.)56.0%A
Grade A: DurableMedian annual gross margin across available fiscal years — pricing-power durability
FCF-Positive Years5/5 yrsA
Grade A: DurableShare of completed fiscal years with positive free cash flow
Net Margin Floor8.4%A
Grade A: DurableWeakest annual net margin across completed fiscal years — recession/downcycle resilience
Per Share
EPS (TTM)$2.13
Own TTM net income / shares — same earnings basis as P/E
Cash / Share$9.16
Cash & short-term investments per share (Finnhub)
Book Value / Share$64.76
Shareholders' equity per share (Finnhub). Negative = accumulated losses / heavy buybacks
Balance Sheet
Total Debt$2.63B
Total debt obligations (short + long term)
Cash & Equiv.$919.86M
Cash and short-term investments
Net Debt$1.71B
Total Debt minus Cash. Negative = Net Cash position
Total Equity$7.25B
Shareholders' equity (book value)
Asset / Liability2.47xA
Grade A: SolidTotal Assets / Total Liabilities
Market
Market Cap$17.03B
Current Market Capitalization
Beta1.09B
Grade B: MarketPrice sensitivity vs the market (Finnhub) — 1.0 moves with market, >1.2 amplifies swings
How grades work: each metric is graded A–D against fixed thresholds (tap a row for the meaning). Card grades map the pillar score to A+–E — a card grade is that pillar's own score, not an average of the rows shown.
Financials as of Jul 2026 · Ratio snapshot Oct 17, 2026
Key Insights: Revvity, Inc. (RVTY)
RVTY is down 1.34% at the last close. Piotroski F-Score of 6/9 indicates mixed fundamentals for Revvity, Inc.. Altman Z-Score of 3.36 sits comfortably in the safe zone (≥ 2.99), indicating low bankruptcy risk. Beneish M-Score of -2.59 suggests a low likelihood of earnings manipulation.
- Revenue has been contracting (CAGR ≈ -7%), which weighs on the growth outlook.
- Revvity, Inc. converts about 19% of revenue into free cash flow — strong cash generation.
- Takes ~3.1 years to repay net debt from free cash flow.
- At a valuation score of 24/100, RVTY trades at a premium to its historical multiples (P/E 71.7).
See how RVTY ranks on the Capex Tracker — top 50 capital spenders compared.
Recent Market Moves
See all RVTY moves →| Date | Session | Price | Move | Z-Score |
|---|---|---|---|---|
| Sep 24 | After-hours | 153.06 | +7.71% | 2.36 |
Frequently Asked Questions about RVTY
What is the current Revvity, Inc. (RVTY) stock price?
RVTY is trading at $152.64 at the last market close, down 1.34% on the session. PreMarketPrice tracks RVTY pre-market, intraday and after-hours prices.
Is RVTY stock a buy right now?
PreMarketPrice's quantitative model rates Revvity, Inc.'s financial health at 65/100. This is a data-driven snapshot of fundamentals, not investment advice.
Is RVTY stock overvalued?
Revvity, Inc. trades at a trailing P/E of 71.7 and our valuation score rates it 24/100 (higher = cheaper vs. its own history). See the Valuation History and Key Metrics sections for forward P/E, EV/EBITDA and PEG context.
When does Revvity, Inc. report earnings?
No confirmed earnings date is currently scheduled for RVTY. The Earnings section lists recent reports and updates as dates are announced.
What sector does Revvity, Inc. operate in?
Revvity, Inc. operates in the Technology sector, within the Laboratory Analytical Instruments industry. The Related Stocks section lists sector peers for comparison.
What does Revvity, Inc. do?
Revvity is a global life sciences and diagnostics company formed in 2023 following the rebranding of PerkinElmer.
About Revvity, Inc. (RVTY) Stock
Revvity, Inc. (RVTY) is a US-listed stock operating in the Technology sector, specifically the Laboratory Analytical Instruments industry. As of the latest update, Revvity, Inc. is trading at $152.64, down 1.34% on the day with a market capitalization of $17.0 billion. The financial health score for RVTY is 65/100, which indicates good financial strength based on profitability, leverage, liquidity, and growth metrics. This page provides real-time pre-market pricing, earnings calendar, financial health analysis, and valuation metrics for RVTY stock.
RVTY Stock Analysis & Key Metrics
On PreMarketPrice, you can track Revvity, Inc. (RVTY) across multiple dimensions:
- Pre-market price & movement: Real-time RVTY stock price with percentage change, updated continuously during pre-market and regular trading hours.
- Valuation & P/E history: Historical P/E, P/S, and P/B ratios for RVTY with trend analysis and normalized valuation multiples.
- Financial statements: Revenue, net income, assets, liabilities, and equity for Revvity, Inc. across multiple reporting periods.
- Financial health score: A composite score of 65/100 based on Altman Z-Score, Piotroski F-Score, profitability, and leverage metrics for RVTY.
- Sector peers: Compare RVTY against 6 other technology stocks on key financial metrics.
Is RVTY a Good Stock to Buy?
This page provides data-driven analysis to help you evaluate Revvity, Inc. (RVTY) as an investment. The financial health score of 65/100 suggests good financial fundamentals. Valuation metrics show whether the stock is trading above or below its historical average.However, this is not financial advice — always do your own research before investing.
Data on this page is sourced from real-time market feeds, Polygon.io, and Finnhub.Revvity, Inc. (RVTY) trades on NYSE/NASDAQ. Pre-market trading occurs 4:00 AM – 9:30 AM ET. Regular market hours are 9:30 AM – 4:00 PM ET.